

Cite this: *Chem. Sci.*, 2017, **8**, 3687

Family-level stereoselective synthesis and biological evaluation of pyrrolomorpholine spiroketal natural product antioxidants†

Alyssa L. Verano^a and Derek S. Tan^{*ab}

The pyranose spiroketal natural products pollenopyrroside A and shensongine A (also known as xylapyrroside A, *ent*-capparisine B) have been synthesized by stereoselective spirocyclizations of a common C1-functionalized glycal precursor. In conjunction with our previously reported syntheses of the corresponding furanose isomers, this provides a versatile family-level synthesis of the pyrrolomorpholine spiroketal natural products and analogues. In rat mesangial cells, hyperglycemia-induced production of reactive oxygen species, which is implicated in diabetic nephropathy, was inhibited by pollenopyrroside A and shensongine A with mid- μ M IC₅₀ values, while unnatural C2-hydroxy analogues exhibited more potent, sub- μ M activity.

Received 16th December 2016
Accepted 27th February 2017

DOI: 10.1039/c6sc05505b
rsc.li/chemical-science

Introduction

Pyrrolomorpholine spiroketals are a novel family of natural products that include both pyranose and furanose isomeric forms and both epimeric configurations at the anomeric carbon (Fig. 1). In 2010, three groups contemporaneously isolated acortatarins A (3) and B (6) from the rhizome of *Acorus tatarinowii*,¹ pollenopyrroside A (1) and B (3) from the bee-collected pollen of *Brassica campestris*,² and capparisines A (3) and B (*ent*-2) from the mature fruit of *Capparis spinosa*.^{3,4} Acortatarin A and a pyranose isomer named acortatarin C (stereochemistry not assigned) were also isolated as bitter components of whole wheat bread crust.⁵

More recently, the epimeric β -spiroketals shensongine A (2) and shensongine B (5) were isolated from capsules of the anti-arrhythmic Chinese herbal medicine Shensong Yangxin, along with shensongine C (4), a C2-hydroxy congener of acortatarin A, and pollenopyrroside B (3).⁶ Contemporaneously, the same β -spiroketals xylapyrroside A (2) and B (5), were isolated from the fungus *Xylaria nigripes*.⁷

The plant-derived sources of these natural products have been used in traditional Chinese medicines for the treatment of a variety of diseases.^{1–3,6,7} Notably, acortatarins A and B exhibit antioxidant activity in a diabetic renal cell model, inhibiting production of reactive oxygen species (ROS) and significantly

attenuating hyperglycemia-induced activation of NADPH oxidase and extracellular matrix production,^{1,8} hallmarks of diabetic nephropathy.^{9a–c} The xylapyrroside also have moderate antioxidant effects and inhibit *t*-butyl hydroperoxide-induced cytotoxicity in rat vascular smooth muscle cells.⁷ Importantly, oxidative stress has been shown to play a critical role in the




Fig. 1 Pyrrolomorpholine spiroketal family of natural products. Structures reflect certain stereochemical revisions made subsequent to the initial isolation reports.⁴ Identical structures isolated from different natural sources and given different names (parentheses) are referred to herein by the first published name.

^aPharmacology Graduate Program, Weill Cornell Graduate School of Medical Sciences, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 422, New York, NY 10065, USA. E-mail: tand@mskcc.org

^bChemical Biology Program and Tri-Institutional Research Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 422, New York, NY 10065, USA

† Electronic supplementary information (ESI) available. See DOI: [10.1039/c6sc05505b](https://doi.org/10.1039/c6sc05505b)



pathogenesis of a wide variety of disease states,⁹ due to the ability of excess ROS to inflict direct damage to essential macromolecules, as well as to lead to aberrant cell signaling.^{10,11} Accordingly, these natural products are of interest based on their therapeutic potential to treat diabetic nephropathy, cardiovascular diseases, and other pathologies in which oxidative stress is implicated.⁹ However, due to the limited quantities available from the natural sources,¹² efficient synthetic access is required for in-depth biological and structure–activity relationship (SAR) studies. As a result, this family of natural products has attracted considerable attention from the synthetic community.^{7,13} We have previously reported concise, highly stereoselective syntheses of the furanose spiroketals acortatarins A (3) and B (6) and shensongine C (4) using stereoselective spirocyclizations of glycal precursors.¹⁴ Herein, we report expansion of this modular approach to a family-level synthesis, providing the naturally-occurring pyranose spiroketals pollennopyrroside A (1) and shensongine A (2, xylapyrroside A, *ent*-capparisine B), as well as corresponding C2-hydroxy analogues, and evaluation of the *in vitro* antioxidant activity of these compounds.

Results and discussion

Retrosynthetic analysis of pyrrolomorpholine spiroketal natural products

The isomeric nature of the pyrrolomorpholine spiroketal natural products presents an attractive opportunity to develop a family-level synthesis that would provide access to both furanose and pyranose congeners, as well as both anomeric stereoisomers.¹⁵ Our laboratory has a long-standing interest in the stereocontrolled synthesis of spiroketals from glycals, with a particular focus on natural product scaffolds for use in probe and drug discovery.¹⁶ Analogous to our approach to the furanose acortatarins,¹⁴ we envisioned that syntheses of the corresponding pyranose isomers could be achieved by stereocontrolled spirocyclization of a pyranoglycal intermediate 7 (Fig. 2). Retrosynthetically, this glycal intermediate 7 would originate from coupling of pyrrole-2,5-dicarboxaldehyde (8) with pyranorabinal (pyranoribal) derivative 9, both of which can be accessed from commercially-available starting materials (10, 11).

Synthesis of shensongine A via acid-catalyzed spirocyclization of pyranorabinal intermediate 16

Thus, we synthesized pyrrole-2,5-dicarboxaldehyde (8) as previously reported.¹⁴ To access the pyranoglycal coupling partner 14, commercially available 3,4-di-*O*-acetyl-D-arabinal (11) was deacetylated¹⁷ then silylated¹⁸ to provide triisopropylsilyl-protected glycal 12 (Fig. 3). This protecting group change was necessary for compatibility with downstream C1-lithiation and also facilitated silica gel purification of intermediates. C1-Formylation¹⁹ of glycal 12 followed by aldehyde reduction provided protected C1-hydroxymethyl arabinal 13. By analogy to our use of the corresponding furanose C1-iodomethyl glycal in our synthesis of the acortatarins,¹⁴ we proceeded with iodination of 13 to give the




Fig. 2 Retrosynthetic strategy via glycal cyclization precursor 7.

pyranose C1-iodomethyl glycal 14a. However, attempted coupling of the iodide 14a with pyrrole 8 under basic conditions led to poor yields of pyrrolomethylglycal 15, due to the susceptibility of the C1-iodomethyl arabinal 14a to decomposition. This is in contrast to the observed stability of the corresponding furanose C1-iodomethyl glycal in our acortatarin syntheses.¹⁴ However, we were able to achieve efficient coupling by instead using the more stable mesylate 14b, which provided the desired coupling product 15 in 71% yield. Aqueous base was required for this *N*-alkylation due to the tendency of pyrrole monomers to dimerize in




Fig. 3 Synthesis of pivotal arabinal intermediate 16. DMF = *N,N*-dimethylformamide; THF = tetrahydrofuran; TIPS = triisopropylsilyl.






Fig. 4 Synthesis of shensongine A (2, xylapyrroside A, *ent*-capparisine B).

nonaqueous conditions.²⁰ Monoreduction of the dialdehyde²¹ with NaBH₄ gave the pivotal spirocyclization precursor **16**, from which pollenopyrroside A and shensongine A would be accessed. Careful monitoring of the reaction allowed for minimal over-reduction and minimal remaining starting material.

Treatment of arabinal **16** with catalytic Brønsted acids led to exclusive formation of the thermodynamic β -spiroketal **17** (Fig. 4). Desilylation furnished shensongine A (2, xylapyrroside A, *ent*-capparisine B), whose optical rotation, NMR, and high-resolution mass spectral data matched those reported for the natural products.²²

Attempted synthesis of pollenopyrroside A *via* mercury-mediated spirocyclization of arabinal intermediates **16** and **18**

In contrast, stereoselective access to the α -anomer, pollenopyrroside A, proved to be more challenging due to the inherent thermodynamic preferences of this [6,6]-spiroketal system. Formation of the contrathermodynamic α -anomer was overwhelmingly disfavored under numerous spirocyclization conditions evaluated.²² By analogy to our previous work in the corresponding furanoribitol-derived [6,5]-spiroketal system,¹⁴ we first attempted Hg-mediated spirocyclization of pyranoarabinal **16**, expecting preferential *anti*-mercuration to form β -mercurinium

intermediate **19**, followed by stereoinvertive cyclization to form an α -spiroketal intermediate (not shown), which could be reduced to the desired α -spiroketal **23** (Fig. 5). However, under these conditions, we instead observed exclusive formation of the β -spiroketal **17**. We attributed this undesired selectivity to steric conflicts between the bulky 3- and/or 4-*O*-TIPS groups and the morpholine ring en route to the α -anomer **23**. In addition, the 3-*O*-TIPS protecting group would preclude an intramolecular hydrogen bond with the morpholine oxygen suggested by the crystal structure of pollenopyrroside A,² which may stabilize the α -configuration. To avoid these issues, we attempted Hg-mediated spirocyclization with the fully deprotected glycal substrate **18**. However, the undesired β -anomer **2** was again formed exclusively. We attributed this undesired stereoselectivity to *syn*-mercuration directed by the free C3-hydroxyl group to form the corresponding α -mercurinium intermediate **21**, followed by stereoinvertive cyclization to β -spiroketal intermediate **22a**. Isolation and NMR analysis of the intermediate 2-mercurial spiroketals as the corresponding chlorides **20b** and **22b** provided stereochemical assignments consistent with these mechanistic interpretations.²³ Use of other mercury salts and less-hindered protecting groups, including a conformationally restricted cyclic carbonate, did not improve stereoselectivity (Table S1†).²²

Synthesis of pollenopyrroside A *via* metal-catalyzed spirocyclization of arabinal intermediate **18**

Based on the intramolecular hydrogen bond between the 3-hydroxyl group and morpholine oxygen postulated from the crystal structure of pollenopyrroside A,² we next pursued a chelation-based approach to favor formation of the desired α -spiroketal (Table 1). Such metal-chelation approaches have been used previously to access contrathermodynamic spiroketals.²⁴ Treatment of β -spiroketal **2** with various metal salts at reflux in CH₃CN or dioxane over 24 h had no effect upon the α : β ratio (Table S2†).²² Treatment of the glycal





Fig. 5 Attempted synthesis of pollenopyrroside A (1) via mercury-mediated spirocyclization. HMDS = hexamethyldisilazide.



Table 1 Metal chelation-based spirocyclization approaches to pollenopyrroside A

Entry	Catalyst	Equiv.	dr ($\alpha : \beta$) ^a	
			α	β
1	MgCl ₂	3.0	n.r. ^b	
2	ZnCl ₂	3.0	n.r.	
3	Ti(O-iPr) ₄	2.0	Decomp. ^c	
4	Sc(OTf) ₃	3.0	60 : 40 ^d	
5	Sc(OTf) ₃ + DTBMP ^e	3.0	n.r.	
6	TfOH	0.2	0 : 100	
7	ScCl ₃	3.0	n.r.	
8	ScCl ₃ + TfOH ^f	3.0	60 : 40	
9	MgCl ₂ + TfOH ^f	3.0	50 : 50	
10	ZnCl ₂ + TfOH ^f	3.0	50 : 50	

^a Determined by ¹H-NMR. ^b n.r. = no reaction. ^c Decomp. = decomposition of starting material. ^d 25% isolated yield of α -spiroketal 1. ^e 1.0 equiv. DTBMP. ^f 0.5 equiv. TfOH; DTBMP = 2,6-di-*t*-butyl-4-methylpyridine.



spirocyclization precursor **18** with MgCl₂, ZnCl₂, or Ti(O-iPr)₄ led to no reaction or decomposition (Table 1, entries 1–3). However, treatment of glycal **18** with Sc(OTf)₃ led to a 60 : 40 ratio of diastereomeric spiroketal products, favoring the desired α -anomer **1** (entry 4). We have recently used Sc(OTf)₃ in stereoselective spirocyclizations of *exo*-glycal epoxides to form benzannulated spiroketsals.^{16e} In those reactions, solvent played a dramatic role, with the catalyst acting as a Lewis acid in THF but as a mild source of triflic acid in CH₂Cl₂.²⁵ To assess the mechanistic basis for the observed selectivity in this substrate system, we carried out a control experiment with DTBMP (2,6-di-*t*-butyl-4-methylpyridine) as an acid scavenger, but no reaction occurred (entry 5), suggesting that the catalyst might, indeed, be serving as a triflic acid source. However, when the reaction was carried out with TfOH alone, we observed complete diastereoselectivity for the undesired β -spiroketal (**2**) (entry 6). Moreover, no reaction was observed upon treatment with ScCl₃ alone (entry 7). In contrast, treatment of glycal **18** with both ScCl₃ and TfOH together (entry 8) recapitulated the 60 : 40 dr observed with Sc(OTf)₃ (entry 4). Notably, combination of MgCl₂ or ZnCl₂ with TfOH also afforded a 50 : 50 mixture of the two diastereomeric spiroketsals **1** and **2**. Taken together, these results suggest that the α -spiroketal **1** is formed under kinetic control, and that both a Lewis acid and Brønsted acid are required to overcome the inherent complete selectivity for the β -spiroketal **2**. This is in contrast to our previous study with *exo*-glycal epoxides, in which Sc(OTf)₃ served as either a Lewis acid or a Brønsted acid source exclusively, depending upon solvent selection.^{16e} Unfortunately, the diastereomeric mixture was

difficult to separate, resulting in only a 25% isolated yield of pollenopyrroside A (**1**).

Synthesis of pollenopyrroside A via methanol-catalyzed kinetic spirocyclization of arabinol intermediate **16**

Thus, to provide more stereoselective access to pollenopyrroside A (**1**), we turned to our previously reported methanol-catalyzed kinetic spirocyclization of glycal epoxides.^{16a,d} While we recognized that this approach would introduce the need for deoxygenation of the resulting 2-hydroxyl group, this was balanced by the much higher stereoselectivity expected with this spirocyclization. In addition, this epoxidation–spirocyclization strategy would provide access to the non-natural 2-hydroxypyranose analogues for biological evaluation, complementing the known 2-hydroxy natural products in the furanose series (**4**, **6**). Accordingly, *anti*-epoxidation of glycal **16** with DMDO was followed by spirocyclization with inversion of configuration in methanol to give the desired α -spiroketal **24** in >98 : 2 dr (Fig. 6a). Desilylation of **24** provided a 2-hydroxy analogue of pollenopyrroside A, **25**, for biological evaluation below. Alternatively, Barton–McCombie deoxygenation²⁶ of **24** at the 2-position and desilylation provided pollenopyrroside A (**1**) in 46% yield over four steps from glycal precursor **16**.

For completeness, we also carried out a stereocomplementary spirocyclization of the glycal epoxide derived from **16** using our previously established Ti(O-iPr)₄-catalyzed kinetic spirocyclization with retention of configuration^{16b} to provide the corresponding β -spiroketal **27** with complete β -diastereoselectivity (Fig. 6b). Desilylation then provided the 2-hydroxy analogue of shensongine A, **28**, for biological evaluation below.

Acid equilibration studies of natural products **1** and **2** and 2-hydroxy analogues **25** and **28**

Acid equilibration experiments under aqueous conditions showed that pollenopyrroside A (**1**) was kinetically stable at pD \geq 5, but underwent complete conversion to its C1-epimer shensongine A (**2**) at pD \leq 4. Conversely, shensongine A was stable down to pD 1, indicating that this β -spiroketal is thermodynamically favored (Fig. 6c). In the 2-hydroxypyranose series, both **25** and its C1-epimer **28** were kinetically stable down to pD 1. Accordingly, epimerization would not be expected for any of these compounds in biological assays under physiologic conditions at pH 7.4.

Evaluation of antioxidant activity of pyrrolomorpholine spiroketsals

Previous reports have demonstrated the antioxidant activity of acortatarin A against high glucose-induced oxidative stress in rat mesangial cells^{1,8} suggesting that this scaffold may have therapeutic potential for the treatment of diabetic nephropathy. Thus, we evaluated the antioxidant activity of the complete α -enantiomeric family of furanose and pyranose pyrrolomorpholine spiroketal natural products and analogues. Intracellular ROS levels were measured using the cell-permeable 2',7'-dichlorofluorescein diacetate (DCFH-DA), which is converted to the highly fluorescent 2',7'-dichlorofluorescein (DCF)






Fig. 6 (a) Synthesis of pollenopyrroside A via MeOH-catalyzed kinetic spirocyclization followed by 2-deoxygenation. (b) Synthesis of 2-hydroxy analogue of shensongine A via Ti(O-i-Pr)₄-mediated kinetic cyclization. (c) Acid equilibration experiments indicate that β -spiroketal shensongine A (2) is thermodynamically favored over α -epimer pollenopyrroside A (1) in aqueous acid ($pD \leq 4$) while 2-hydroxy analogues 25 and 28 do not equilibrate down to pD 1. DMDO = dimethyldioxirane; AIBN = azobisisobutyronitrile.

upon deacetylation by intracellular esterases and oxidation.^{27,28} Rat mesangial cells are highly sensitive to hyperglycemic conditions, and a significant increase in ROS was observed after 3 h exposure to 30 mM D-glucose.²² Inhibition of high glucose-induced oxidative stress was evaluated by concomitant treatment with the pyrrolomorpholine spiroketals, or with 1 mM N-acetylcysteine, a precursor of the antioxidant glutathione, as a positive control.²⁹

Consistent with the previous report,¹ acortatarins A (3) and B (6) reduced high glucose-induced ROS generation in a dose-dependent manner, with IC₅₀ values of 4.6 and 11 μ M, respectively, returning ROS levels to that of normal glucose conditions (Table 2, entries 2, 5). Compared to acortatarin A (3), the β -spiroketal shensongine B (5) was 4-fold less potent (entries 2,

Table 2 Inhibition of high glucose-induced ROS production in rat mesangial cells^a

Entry	Compound	IC ₅₀ (μ M) [s.d. log IC ₅₀] ^b	Maximum % ROS inhibition ^c
1	N-Acetylcysteine ^d	n.a.	100%***
2	Acortatarin A (3)	4.6 [0.15]	100%***
3	Shensongine B (5)	19 [0.05]	100%***
4	Shensongine C (4)	4.8 [0.07]	100%***
5	Acortatarin B (6)	11 [0.07]	100%***
6	Pollenopyrroside A (1)	17 [0.01]	100%***
7	Shensongine A (2)	11 [0.05]	100%***
8	2-OH pollenopyrroside A (25)	0.52 [0.04]	80%***
9	2-OH shensongine A (28)	0.27 [0.04]	60%***

^a Cells were treated with compound (0–3 mM) under normal (5.6 mM) or high (30 mM) glucose conditions and overall ROS levels were measured using the fluorescent probe DCFH-DA (50 μ M).²² ^b Data are expressed as geometric mean IC₅₀ (antilog [mean log IC₅₀]) of three independent experiments, each performed in triplicate, with the standard deviation of the log IC₅₀ shown in brackets. ^c Statistical significance relative to untreated cells under high-glucose conditions was assessed using a two-tailed unpaired Student *t*-test with 95% confidence intervals; ****p* ≤ 0.001. ^d N-Acetylcysteine (1 mM) was used as a positive control.

3), suggesting that the spiroketal stereocenter may be important for activity. Consistent with this trend, the α -spiroketal shensongine C (4) was also more potent than its β -spiroketal congener acortatarin B (6) (entries 4, 5).

In the pyranose spiroketal series, both pollenopyrroside A (1) and shensongine A (2) also reduced ROS in a dose-dependent manner, with comparable IC₅₀ values of 17 and 11 μ M, respectively, returning ROS levels to that of normal glucose conditions (entries 6, 7). Notably, the corresponding 2-hydroxy analogues 25 and 28 were much more potent inhibitors, with IC₅₀ values of 0.52 and 0.27 μ M, respectively, albeit affording only partial rescues (80% and 60% maximum inhibition, respectively). Surprisingly, these analogues exhibited U-shaped dose-response curves with ROS levels actually increasing at higher concentrations (\geq 100 μ M and \geq 30 μ M, respectively),²² possibly due to as yet undetermined feedback, off-target, or non-specific mechanisms.³⁰ None of the other compounds exhibited U-shaped dose-response curves up to the maximum concentration tested (3000 μ M), however, as these compounds have 9- to 70-fold higher IC₅₀ values than 25 and 28, such effects cannot be ruled out at even higher concentrations.

Conclusions

In conclusion, we have developed an efficient, stereoselective, family-level synthesis of the pyrrolomorpholine spiroketal natural products, providing access to pollenopyrroside A (1) and shensongine A (2), as well as the corresponding 2-hydroxy analogues (25, 28), from the common pyranoarabinol intermediate 16. Pollenopyrroside A was synthesized in 11 steps and 15% overall yield from 3,4-di-O-acetyl-D-arabinal, and shensongine A was accessed in 9 steps and 28% overall yield. Complete diastereoselectivity was achieved for the key



spiroketal-forming steps toward both natural products, as well as the 2-hydroxy congeners. This compares favorably to previous syntheses,^{7,13f,g,31} and provides practical access to the natural products and a variety of analogues. Indeed, while the synthesis of pollenopyrroside A involved an epoxidation–cyclization strategy that required subsequent C2-deoxygenation to afford the natural product, this route also provided convenient access to the corresponding 2-hydroxy analogues, which have not yet been described in the pyranose series but are known as natural products in the isomeric furanose series (*i.e.*: 4, 6). Evaluation of antioxidant activity against hyperglycemia-induced ROS in rat mesangial cells indicated similar activities for the anomeric natural products pollenopyrroside A (1) and shensongine A (2). Strikingly, the 2-hydroxy analogues 25 and 28 exhibited 30- to 40-fold lower IC₅₀ values compared to the natural products, albeit with incomplete ROS inhibition due to U-shaped dose response curves. Notably, in the furanose series, the α -spiroketals acortatarin A (3) and shensongine C (4) were considerably more potent than the β -anomers, shensongine B (5) and acortatarin B (6), although this trend did not extend to the pyranose series (*cf.* 1, 2). Overall, this family-level synthesis allowed the first direct comparison of the antioxidant activities of the entire D-enantiomeric series of furanose and pyranose isomers, and led to the discovery of novel 2-hydroxy analogues with potent, sub- μ M IC₅₀ values. These more potent analogues may be useful for mechanistic studies, including target identification efforts. Further investigation into the mechanisms of action of these compounds and additional analogues are ongoing and will be reported in due course.

Acknowledgements

We thank Prof. Anthony Sauve (Weill Cornell Medicine) for helpful discussions and access to cell culture facilities, Dr Kristin Kirschbaum (University of Toledo) for helpful discussions, and Dr George Sukenick and Dr Rong Wang, (MSK) for expert NMR and mass spectral support. Financial support from the NIH (P41 GM076267 to D. S. T.; T32 CA062948-Gudas to A. L. V., CCSG P30 CA008748 to C. B. Thompson) and PhRMA Foundation (predoctoral fellowship to A. L. V.) is gratefully acknowledged.

Notes and references

- 1 X. Tong, L. Zhou, Y. Wang, C. Xia, Y. Wang, M. Liang, F. Hou and Y. Cheng, *Org. Lett.*, 2010, **12**, 1844–1847.
- 2 J. Guo, Z. Feng, Y. Yang and Z. Zhang, *Chem. Pharm. Bull.*, 2010, **58**, 983–985.
- 3 T. Yang, C. Wang, G. Chou, T. Wu, X. Cheng and Z. Wang, *Food Chem.*, 2010, **123**, 705–710.
- 4 Several of the original stereochemical assignments have been revised based on total synthesis and/or X-ray crystallographic analysis using CuK α radiation, which enables assignment of absolute configuration. The revised structures based on current understanding are shown in Fig. 1. See ESI,† Section F for a complete discussion and relevant references.
- 5 D. Jiang and D. G. Peterson, *Food Chem.*, 2013, **141**, 1345–1353.
- 6 B. Ding, Y. Dai, Y.-L. Hou and X.-S. Yao, *J. Asian Nat. Prod. Res.*, 2015, **17**, 559–566.
- 7 M. Li, J. Xiong, Y. Huang, L.-J. Wang, Y. Tang, G.-X. Yang, X.-H. Liu, B.-G. Wei, H. Fan, Y. Zhao, W.-Z. Zhai and J.-F. Hu, *Tetrahedron*, 2015, **71**, 5285–5295.
- 8 Z. Zhao, L. Zhou, X. Chen, Y. Cheng, F. Hou and J. Nie, *Chin. Med. J.*, 2013, **126**, 1230–1235.
- 9 Role of oxidative stress in diabetic nephropathy: (a) J. M. Forbes, M. T. Coughlan and M. E. Cooper, *Diabetes*, 2008, **57**, 1446–1454; (b) N. Kashihara, Y. Haruna, V. K. Kondeti and Y. S. Kanwar, *Curr. Med. Chem.*, 2010, **17**, 4256–4269; (c) D. M. Small, J. S. Coombes, N. Bennet, D. W. Johnson and G. C. Gobe, *Nephrology*, 2012, **17**, 311–321. Neurodegenerative disease: (d) J. Emerit, M. Edeas and F. Bricaire, *Biomed. Pharmacother.*, 2004, **58**, 39–46; (e) B. Uttara, A. V. Singh, P. Zamboni and R. T. Mahajan, *Curr. Neuropharmacol.*, 2009, **7**, 65–74. Cardiovascular disease: (f) N. R. Madamanchi, A. Vendrov and M. S. Runge, *Arterioscler., Thromb., Vasc. Biol.*, 2005, **25**, 29–38.
- 10 D. Giustarini, I. Dalle-Donne, D. Tsikas and R. Rossi, *Crit. Rev. Clin. Lab. Sci.*, 2009, **46**, 241–281.
- 11 R. A. Roberts, D. L. Laskin, C. V. Smith, F. M. Robertson, E. M. G. Allen, J. A. Doorn and W. Slikker, *Toxicol. Sci.*, 2009, **112**, 4–16.
- 12 *A. tatarinowii* root (50 kg) yielded 7.3 mg acortatarin A (0.000015 wt%) and 3.4 mg acortatarin B (0.000007 wt%) (ref. 1); *B. campestris* pollen (15 kg) yielded 6 mg pollenopyrroside A (0.000040 wt%) and 5 mg pollenopyrroside B (acortatarin A) (0.000033 wt%) (ref. 2); *C. spinosa* powdered fruits (10 kg) yielded 4 mg capparisine A (acortatarin A) (0.000040 wt%) and 5 mg capparisine B (0.000050 wt%) (ref. 3); powdered Shensong Yangxin (2 kg) yielded 8.1 mg shensongine A (0.000405 wt%), 2.8 mg shensongine B (0.000140 wt%), 15.5 mg shensongine C (0.000775 wt%), as well as 14.8 mg pollenopyrroside B (0.000740 wt%) (ref. 6); *X. nigripes* mycelium (20 kg) yielded 4.0 mg xylapyrroside A (0.000020 wt%) and 21.3 mg xylapyrroside B (0.000107 wt%), as well as 1.2 mg pollenopyrroside A (0.000006 wt%) and 20.1 mg acortatarin A (0.000100 wt%) (ref. 7).
- 13 For syntheses of pyrrolomorpholine spiroketal natural products, see: (a) G. Sudhakar, V. D. Kadam, S. Bayya, G. Pranitha and B. Jagadeesh, *Org. Lett.*, 2011, **13**, 5452–5455; (b) H. M. Geng, J. L. Chen, D. P. Furtkert, S. Jiang and M. A. Brimble, *Synlett*, 2012, **23**, 855–858; (c) N. V. Borrero and A. Aponick, *J. Org. Chem.*, 2012, **77**, 8410–8416; (d) T. Teranishi, M. Kageyama and S. Kuwahara, *Biosci., Biotechnol., Biochem.*, 2013, **77**, 676–678; (e) P. Cao, Z.-J. Li, W.-W. Sun, S. Malhotra, Y.-L. Ma, B. Wu and V. S. Parmar, *Nat. Prod. Bioprospect.*, 2015, **5**, 37–45; (f) Z. Cao, Y. Li, S. Wang, X. Guo, L. Wang and W. Zhao, *Synlett*, 2015, **26**, 921–926; (g) J. M. Wood, D. P. Furtkert and M. A. Brimble, *Org. Biomol. Chem.*, 2016, **14**, 7659–7664.
- 14 J. M. Wurst, A. L. Verano and D. S. Tan, *Org. Lett.*, 2012, **14**, 4442–4445.



15 S. A. Snyder, A. Gollner and M. I. Chiriac, *Nature*, 2011, **474**, 461–466.

16 (a) J. S. Potuzak, S. B. Moilanen and D. S. Tan, *J. Am. Chem. Soc.*, 2005, **127**, 13796–13797; (b) S. B. Moilanen, J. S. Potuzak and D. S. Tan, *J. Am. Chem. Soc.*, 2006, **128**, 1792–1793; (c) G. Liu, J. M. Wurst and D. S. Tan, *Org. Lett.*, 2009, **11**, 3670–3673; (d) J. M. Wurst, G. Liu and D. S. Tan, *J. Am. Chem. Soc.*, 2011, **133**, 7916–7925; (e) I. Sharma, J. M. Wurst and D. S. Tan, *Org. Lett.*, 2014, **16**, 2474–2477; (f) Reviewed in: A. L. Verano and D. S. Tan, *Isr. J. Chem.*, DOI: 10.1002/ijch.201600134.

17 A. J. Janczuk, W. Zhang, P. R. Andreana, J. Warrick and P. G. Wang, *Carbohydr. Res.*, 2002, **337**, 1247–1259.

18 H. Abe, S. Shut, S. Tamura and A. Matsuda, *Tetrahedron Lett.*, 2001, **42**, 6159–6161.

19 J. Robertson, P. T. Chovatia, T. F. Fowler, J. M. Withey and D. J. Woollaston, *Org. Biomol. Chem.*, 2010, **8**, 226–233.

20 J. M. Muchowski and P. Hess, *Tetrahedron Lett.*, 1988, **29**, 777–780.

21 Monoreduction of diformylpyrrole: (a) R. Li, A. D. Lammer, G. M. Ferrence and T. D. Lash, *J. Org. Chem.*, 2014, **79**, 4078–4093; (b) Y.-W. Chin, S. W. Lim, S.-H. Kim, D.-Y. Shin, Y.-G. Suh, Y.-B. Kim, Y. C. Kim and J. Kim, *Bioorg. Med. Chem. Lett.*, 2003, **13**, 79–81.

22 See ESI† for complete details.

23 NMR analysis of the 2-mercurial intermediates, isolated after brine workup prior to NaBH_4 reduction, indicated that substrate **16** undergoes *anti*-mercuration, while **18** undergoes *syn*-mercuration, presumably due to directing effects of the free hydroxyl groups.

24 For syntheses of spiroketals in which metal chelation effects are postulated, see: (a) D. R. Williams, P. A. Jass and R. D. Gaston, *Tetrahedron Lett.*, 1993, **34**, 3231–3234; (b) D. A. Evans, B. W. Trotter, P. J. Coleman, B. Côté, L. C. Dias, H. A. Rajapakse and A. N. Tyler, *Tetrahedron*, 1999, **55**, 8671–8726; (c) A. B. Smith, V. A. Doughty, Q. Lin, L. Zhuang, M. D. McBriar, A. M. Boldi, W. H. Moser, N. Murase, K. Nakayama and M. Sobukawa, *Angew. Chem., Int. Ed.*, 2001, **40**, 191–195; (d) J. L. Hubbs and C. H. Heathcock, *J. Am. Chem. Soc.*, 2003, **125**, 12836–12843; (e) S. F. Tlais and G. B. Dudley, *Org. Lett.*, 2010, **12**, 4698–4701; (f) M. J. Kurth, E. G. Brown, E. Hendra and H. Hope, *J. Org. Chem.*, 1985, **50**, 1115–1117.

25 (a) T. C. Wabnitz, J. Yu and J. B. Spencer, *Chem.-Eur. J.*, 2004, **10**, 484–493; (b) D. C. Rosenfeld, S. Shekhar, A. Takemiya, M. Utsunomiya and J. F. Hartwig, *Org. Lett.*, 2006, **8**, 4179–4182; (c) T. T. Dang, F. Boeck and L. Hintermann, *J. Org. Chem.*, 2011, **76**, 9353–9361.

26 S. Iacono and J. R. Rasmussen, *Org. Synth.*, 1986, **64**, 57–62.


27 H. Wang and J. A. Joseph, *Free Radical Biol. Med.*, 1999, **27**, 612–616.

28 L. M. Magalhães, M. A. Segundo, S. Reis and J. L. F. C. Lima, *Anal. Chim. Acta*, 2008, **613**, 1–19.

29 K.-Y. Hung, S.-Y. Liu, S.-H. Kao, J.-W. Huang, C.-K. Chiang and T.-J. Tsai, *Am. J. Nephrol.*, 2009, **29**, 192–202.

30 The eight pyrrolomorpholine natural products and 2-hydroxy analogues were not similar to known aggregators, as assessed by the Aggregator Advisor database, <http://advisor.bkslab.org/>; J. J. Irwin, D. Duan, H. Torosyan, A. K. Doak, K. T. Ziebart, T. Sterling, G. Tumanian and B. K. Shoichet, *J. Med. Chem.*, 2015, **58**, 7076–7087.

31 Ref. 7 provided shensongine A in 13.7% yield over 11 steps, with the key spirocyclization proceeding in >98 : 2 diastereoselectivity to the thermodynamic β -spiroketal. Ref. 13f provided pollenopyrroside A in 2.7% yield and shensongine A in 8.8% yield over 14 steps with the key spirocyclization proceeding in 1 : 3 α/β dr. Ref. 13g provided pollenopyrroside A in 5.6% yield and shensongine A in 0.79% yield over 11 steps, with the key spirocyclization proceeding in 1.2 : 1 dr as an inseparable mixture of unassigned diastereomers.



24 For syntheses of spiroketals in which metal chelation effects are postulated, see: (a) D. R. Williams, P. A. Jass and

